IL2RA and glioblastoma: In a phase I clinical trial in glioblastoma, treatment with the anti-IL-2Rα monoclonal antibody daclizumab in combination with EGFRvIII peptide vaccination, significantly reduced the frequency of circulating Tregs [75].